21 May 2013
Keywords: axcan, urso, efficacy, says, firm, pharma, maintains
Article | 12 August 2002
Axcan Pharma maintains that a Phase II trial of its URSO 250 (ursodiol)has achieved positive results, even though it missed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 January 2003
20 May 2013
© 2013 thepharmaletter.com